July 11, 2023 11:01 AM EDT

Bristol Myers reinforces neuroscience deals; Iovance prices $150M public offering

Kyle LaHucik

Senior Reporter

Paul Schloesser

Associate Editor

Bristol Myers Squibb, a big pharma hardly synonymous with neuroscience drugs, is beefing up its work with two European biotechs in Alzheimer’s and undisclosed neurodegenerative …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers reinforces neuroscience deals; Iovance prices $150M public offering

Kyle LaHucik

Senior Reporter

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?

Bris­tol My­ers re­in­forces neu­ro­science deals; Io­vance prices $150M pub­lic of­fer­ing

Senior Reporter

Associate Editor

Sign up to read this article for free.

Bristol Myers reinforces neuroscience deals; Iovance prices $150M public offering